Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.36 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.31 |
| ▸ | FEN1 | P39748 | 3/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091343 | 0.95 | OPRL1 (0.38) | OPRL1CNR1CNR2KDM1A | |
| SCHEMBL14922512 | 0.94 | FPR2 (0.36) | OPRL1FPR2CNR1CNR2ALOX5AP | |
| SCHEMBL11933105 | 0.94 | FPR2 (0.36) | FPR2ALOX5APFEN1AAK1KDM1A | |
| SCHEMBL11933324 | 0.92 | ALOX5AP (0.37) | FPR2CNR1CNR2ALOX5APFEN1 | |
| SCHEMBL11933111 | 0.92 | ALOX5AP (0.37) | FPR2CNR1CNR2ALOX5APFEN1 | |
| SCHEMBL12197368 | 0.91 | OPRL1 (0.36) | OPRL1CNR1CNR2KDM1A | |
| SCHEMBL11933108 | 0.91 | CTSL (0.33) | OPRL1FPR2 | |
| SCHEMBL11933106 | 0.91 | CTSL (0.33) | OPRL1FPR2 | |
| SCHEMBL12196829 | 0.91 | OPRL1 (0.33) | OPRL1FPR2CNR1CNR2ALOX5AP | |
| SCHEMBL12196576 | 0.90 | FPR2 (0.34) | FPR2ALOX5APFEN1KDM1AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | OPRL1 1746/4885FPR2 1970/4885CNR1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.